Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Myol ; 32(2): 100-5, 2013 Oct.
Article in English | MEDLINE | ID: mdl-24399867

ABSTRACT

Patients with muscle pathology are a challenge for anaesthesiologists because of possible life-threatening general anaesthesia complications. A review of the current medical literature on the issue clearly indicates that increasing awareness by anaesthesiologists in recent years has led to a reduction in the occurrence of adverse events in patients with diagnostically well-defined muscle disease. On the other hand, the current emerging aspect is that the great majority of complications concern subjects with clinically non-overt (silent to mildly symptomatic) and thus undiagnosed myopathy. With a view to improving prevention of possible critical anaesthesia complications in such patients, we present a "Safe Anaesthesia Table", listing both the anaesthetic drugs to be avoided and those considered harmless for myopathic patients, irrespective of age and type of pathology. In addition, a brief outline about the clinical aspects suggestive of a possible muscle pathology is also provided. Using "safe drugs" during routine surgical procedures in subjects with suspected undiagnosed myopathy will enable the anaesthesiologist to avoid delaying surgery, while protecting them from anaesthesia complications. By following this approach the presumed myopathy can be properly investigated after surgery.


Subject(s)
Anesthetics , Diagnostic Errors/prevention & control , Drug-Related Side Effects and Adverse Reactions , Muscular Diseases , Adult , Anesthesia/methods , Anesthetics/administration & dosage , Anesthetics/adverse effects , Anesthetics/classification , Asymptomatic Diseases , Child , Contraindications , Drug Monitoring/methods , Drug-Related Side Effects and Adverse Reactions/classification , Drug-Related Side Effects and Adverse Reactions/etiology , Drug-Related Side Effects and Adverse Reactions/physiopathology , Drug-Related Side Effects and Adverse Reactions/prevention & control , Humans , Muscular Diseases/complications , Muscular Diseases/diagnosis , Muscular Diseases/physiopathology , Patient Harm/prevention & control , Preoperative Care/methods
2.
In Vivo ; 20(6A): 703-6, 2006.
Article in English | MEDLINE | ID: mdl-17203749

ABSTRACT

Peritoneal carcinomatosis has always been regarded as a contraindication in traditional cancer surgery treatment; however, good results have been reported by using new combined medical-surgical loco-regional techniques. Peritonectomy and chemohyperthermic perfusion with cisplatinum (CIIP) seem to play a central role in obtaining a better survival rate than with the traditional procedures, even though there is a cisplatinum nephrotoxic effect. The aim of this study was to investigate entity and type of renal injury after CIIP. Forty-two patients (12 males and 30 females) with recurrent or primary peritoneal carcinomatosis who underwent peritonectomy and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy with cisplatin were enrolled. A significant worsening in renal function was observed on the third post-operative day and this condition then persisted for three months. A reduction in estimated-Glomerular Filtration Rate (e-GFR) and an alteration in the albumin:creatinine ratio proved tubular injury. On the third post-operative day after cisplatinum administration, a high toxicity peak was found following platinum free fraction excretion. Proximal tubular injury was confirmed even at the three month analysis. A significant correlation between the total protein reduction rate and the decrease in renal function was established. In relation to that, the platinum free fraction could increase because of a binding protein shortage and the nephrotoxic effect could be enhanced due to platinum accumulation within the post-operative period. This finding suggests that the higher the protein reduction is, the lower the e-GFR determination is at three months.


Subject(s)
Antineoplastic Agents/adverse effects , Carcinoma/therapy , Cisplatin/adverse effects , Kidney Diseases/chemically induced , Kidney Tubules/drug effects , Peritoneal Neoplasms/drug therapy , Peritoneum/surgery , Albuminuria/diagnosis , Albuminuria/urine , Chemotherapy, Cancer, Regional Perfusion , Combined Modality Therapy , Creatine/urine , Female , Glomerular Filtration Rate/drug effects , Humans , Hyperthermia, Induced , Kidney Diseases/metabolism , Kidney Diseases/physiopathology , Kidney Tubules/metabolism , Kidney Tubules/physiopathology , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...